EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease

Shohei Nakamura, Yasuhiro Katsumata, Yuko Okamoto, Masayoshi Harigai

Rheumatology & Autoimmunity · 2026-09 · 6 (3) · 186-194

DOI: 10.1002/rai2.70053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology & Autoimmunity, online erschienen am 14.05.2026. Verfasst von Shohei Nakamura und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rapidly progressive interstitial lung disease (ILD) is a major complication in patients with anti‐melanoma differentiation‐associated gene 5 (MDA5)‐positive dermatomyositis (DM) and carries a poor prognosis despite aggressive immunosuppressive therapy. Emerging evidence suggests that overactivation of the type I interferon (IFN‐I) pathway may play a pivotal role in the pathogenesis of this disease. This study aimed to evaluate the activation of the IFN‐I pathway in the sera of patients with MDA5‐positive DM‐associated ILD.

Methods

Serum samples were collected from clinically active patients with anti‐MDA5‐positive DM‐associated ILD and anti‐aminoacyl‐tRNA synthetase (ARS)‐positive polymyositis (PM)/DM‐associated ILD and healthy controls ( n = 22, 21, and 32, respectively). Serum IFN‐I bioactivity, IFN‐stimulated gene (ISG)‐inducing activity, and nuclear factor kappa B (NF‐κB) bioactivity were determined using reporter cell lines. The relationship between these results and clinical features was analyzed.

Results

The sera of patients with anti‐MDA5‐positive DM‐associated ILD demonstrated significantly higher IFN‐I bioactivity and ISG‐inducing activity than those with anti‐ARS‐positive PM/DM‐associated ILD and healthy controls ( p < 0.01 for all comparisons). In contrast, no significant differences in NF‐κB bioactivity were observed. Serum IFN‐I bioactivity and ISG‐inducing activity were moderately correlated with serum ferritin levels ( r = 0.53 and 0.54, respectively). In an exploratory analysis, the serum of six patients with anti‐MDA5‐positive DM‐associated ILD demonstrated higher ISG‐inducing activity than that measured using reporter cells with a knockout of the IFNAR2 gene, and higher values of IFN‐I bioactivity, ISG‐inducing activity, and serum ferritin than the other samples, suggesting IFN‐I overactivation, especially in these patients.

Conclusions

This study confirmed the hypothesis that the overactivation of the serum IFN‐I pathway is strongly associated with anti‐MDA5‐positive DM‐associated ILD. In addition, anti‐MDA5‐positive DM‐associated ILD and anti‐ARS‐positive PM/DM‐associated ILD may have distinct pathomechanisms.

Zitieren

APA

Nakamura, S., Katsumata, Y., Okamoto, Y., & Harigai, M. (2026). Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease. Rheumatology & Autoimmunity, 6(3), 186-194. https://doi.org/10.1002/rai2.70053

Vancouver

Nakamura S, Katsumata Y, Okamoto Y, Harigai M. Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease. Rheumatology & Autoimmunity. 2026;6(3):186-194. doi:10.1002/rai2.70053

BibTeX
@article{Nakamura2026,
  author = {Nakamura, Shohei and Katsumata, Yasuhiro and Okamoto, Yuko and Harigai, Masayoshi},
  title = {Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease},
  journal = {Rheumatology & Autoimmunity},
  year = {2026},
  volume = {6},
  number = {3},
  pages = {186--194},
  doi = {10.1002/rai2.70053}
}
Kostenlos starten →